Health
Scientists find clues on why COVID vaccine causes chronic health problems in some
For a majority of people, the COVID vaccine doesn’t cause adverse health effects — but a small percentage experience chronic symptoms that can last for months or even years.
Yale researchers recently made some discoveries about why certain people experience this condition, which they have dubbed “post-vaccination syndrome” (PVS).
In early findings, the team recognized “potential immunological patterns” that are unique to people with PVS. The hope is that this discovery will help to enable future treatments and therapies for those who are affected.
IS MMR VACCINE SAFE FOR KIDS? DR. NICOLE SAPHIER ADDRESSES CONCERNS AS MEASLES CASES RISE
“This work is still in its early stages, and we need to validate these findings,” said co-senior study author Akiko Iwasaki, Sterling Professor of Immunobiology at Yale School of Medicine, in a press release.
Yale researchers recently made some discoveries about why certain people experience “post-vaccination syndrome” (PVS). (iStock)
“But this is giving us some hope that there may be something that we can use for diagnosis and treatment of PVS down the road.”
Symptoms of post-vaccination syndrome
People with this condition may suffer from excessive fatigue, exercise intolerance, brain fog, insomnia and dizziness, according to the Yale researchers.
These typically develop within a day or two of vaccination and can worsen over time.
NEW BAT CORONAVIRUS DISCOVERED IN CHINA SPARKS PANDEMIC CONCERNS
“It’s clear that some individuals are experiencing significant challenges after vaccination. Our responsibility as scientists and clinicians is to listen to their experiences, rigorously investigate the underlying causes, and seek ways to help,” said co-senior author Harlan Krumholz, professor of cardiology at YSM, in the release.
“Post-vaccination syndrome is real, and has been found [to occur] from many vaccines, including COVID,” Dr. Marc Siegel, clinical professor of medicine at NYU Langone Health and Fox News senior medical analyst, told Fox News Digital.
What the study found
The researchers analyzed blood samples from 42 study participants who experienced symptoms of PVS and 22 who did not.
Those with symptoms were shown to have lower levels of two types of white blood cells. People with PVS who had never had COVID also had lower levels of antibodies against the SARS-CoV-2 spike protein, likely because they tended to have fewer vaccine doses, according to the release.
“Post-vaccination syndrome is real, and has been found [to occur] from many vaccines.”
“Fewer vaccine doses and no viral infection means the body’s immune system has had little opportunity to develop a defense to the virus,” said the researchers.
Some of the people with PVS also had higher levels of the SARS-CoV-2 spike protein, which enables the virus to penetrate and infect host cells. This has also been linked to a higher risk of developing long COVID.
“We don’t know if the level of spike protein is causing the chronic symptoms, because there were other participants with PVS who didn’t have any measurable spike protein — but it could be one mechanism underlying this syndrome,” said Iwasaki.
People with the syndrome may suffer from excessive fatigue, exercise intolerance, brain fog, insomnia and dizziness, according to the Yale researchers. (iStock)
In addition to the elevated spike proteins, other factors could increase the risk of post-vaccination syndrome. Those include autoimmunity, tissue damage and reactivation of Epstein-Barr virus (EBV), the researchers wrote.
“Akiko Iwasaka is a world-renowned immunologist at Yale who has studied COVID (and COVID vaccines) extensively,” Siegel pointed out.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“In this new study, she reports that in a very small percentage of those who received COVID vaccines (and experienced prolonged side effects), there may be the presence of persistent spike protein,” Siegel confirmed.
“They may also experience immune disruption, which takes the form of elevations in inflammatory immune cells (CD8 and TN alpha) and a decrease in cells that help resolve inflammation and infection (CD4 helper cells).”
“Every medical intervention carries some risk, and it’s important to acknowledge that adverse events can occur with vaccines.” (REUTERS/Dado Ruvic/Illustration/File Photo)
The researchers agreed that more studies are essential to guide diagnosis and treatment.
“We’re only just starting to make headway in understanding PVS,” said Krumholz. “Every medical intervention carries some risk, and it’s important to acknowledge that adverse events can occur with vaccines.”
For more Health articles, visit www.foxnews.com/health
“Our focus must remain on understanding what these people are experiencing through rigorous science and addressing the needs of those affected with compassion and an open mind.”
Siegel agreed, adding, “This needs to be further studied in terms of understanding how common prolonged COVID vaccine side effects are and how to predict them and treat them.”
NEWYou can now listen to Fox News articles!
A new injectable therapy is showing positive results in reducing melanoma throughout a five-year period.
The personalized mRNA cancer therapy, called intismeran autogene, combined with the cancer immunotherapy drug KEYTRUDA (pembrolizumab), is a collaboration between Merck and Moderna.
The results from the phase 2b KEYNOTE-942 study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on May 27.
CLICK HERE FOR MORE HEALTH STORIES
After about a five-year follow-up, the combo drug was found to reduce the risk of melanoma recurrence or death by 49% compared to pembrolizumab alone.
The researchers analyzed data from 157 patients with high-risk stage 3 and 4 melanoma whose cancer had been removed via surgery. The participants were split into two groups — one received the combo therapy and the other only received pembrolizumab, according to a press release.
The therapy was found to reduce the risk of melanoma recurrence or death by 49% compared to pembrolizumab alone after a five-year follow-up. (iStock)
The findings revealed that the combination group saw benefits that were “sustained and durable over time.”
Intismeran autogene is designed using mutations identified in a patient’s own tumor, with the intention of teaching the immune system what the cancer looks like so that it can recognize and attack it.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
According to the researchers, intismeran is “well-tolerated” with a “manageable” safety profile.
The most commonly cited side effects of the personalized mRNA vaccine plus KEYTRUDA were fatigue, injection-site pain, chills, fever and headache. The researchers reported no new long-term safety concerns and no severe vaccine-related adverse events.
The combination therapy is currently being evaluated in a phase 3 study — the final confirmation stage.
Patients with late-stage melanoma have a “significant risk” of cancer recurrence, according to an expert. (iStock)
In a Merck press release from January, Kyle Holen, MD, Moderna’s senior vice president and head of development, oncology and therapeutics, noted that this data highlights the “potential of a prolonged benefit … in patients with resected high-risk melanoma.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“We continue to invest in our platform in oncology because of encouraging outcomes like these, which illustrate mRNA’s potential in cancer care,” he said.
Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, also commented that for many patients with stage 3 or 4 melanoma, there is a “significant risk of recurrence following surgery.”
Researchers confirmed that the combination therapy is currently being evaluated in a phase 3 study. (iStock)
“As such, demonstrating the longer-term potential of intismeran autogene and KEYTRUDA to reduce the risk of recurrence for certain patients with melanoma is a meaningful milestone,” she said.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
The company cited encouraging five-year follow-up data and pointed to upcoming late-stage INTerpath trial results with Moderna in several hard-to-treat cancers.
NEWYou can now listen to Fox News articles!
An accidental lab discovery has opened the door to entirely new ways of preventing the flu.
While investigating how influenza replicates, researchers discovered that different flu strains use completely different strategies to infiltrate human cells, SWNS reported.
By targeting the specific molecules the viruses rely on, scientists found that they could block them from entering new cells and halt their replication altogether.
5 THINGS YOU NEED TO KNOW BEFORE GETTING YOUR FLU SHOT, ACCORDING TO DOCTORS
Researchers say these “fundamental insights” into seasonal influenza highlight a clear path toward developing better preventive medications.
“The hope is that fundamental, curiosity-based research like this helps to pave the way for novel strategies to treat and prevent influenza infections,” principal investigator Dr. Emily Bruce, from the University of Vermont’s Larner College of Medicine, said in the SWNS report.
While investigating how influenza replicates, researchers discovered that different flu strains use completely different strategies to infiltrate human cells. (iStock)
While several flu strains cause illness, H1N1 and H3N2 influenza A viruses are the most common. However, current flu tests cannot differentiate between them, and clinical treatments are identical for both.
Although vaccines and antivirals are available, Bruce noted a “dire” need for better medications to stop the virus from spreading cell to xxcell.
“You don’t get sick when a virus is in one cell,” he noted. “You get sick because a virus replicates itself and goes into many more cells.”
HOW LONG YOU’RE CONTAGIOUS WITH THE FLU — AND WHEN IT’S SAFE TO GO OUT
The study, which was published in The Journal of Virology, originally aimed to map how viral RNA segments are transported within cells to create new viral particles.
The team used H1N1 and H3N2 viruses isolated from the nasal passages of positive patients in 2022.
Clinical treatments remain identical for both primary strains of the flu virus. (iStock)
During the investigation, the team unexpectedly stumbled upon a cellular pathway that blocked the virus from entering lung cells, SWNS reported.
RESEARCHERS LOCKED FLU PATIENTS IN A HOTEL WITH HEALTHY ADULTS — NO ONE GOT SICK
The data revealed that when a specific human protein called Rab11B was depleted, H3N2 viruses failed to enter human lung cells. H1N1 viruses were completely unaffected.
Using reverse genetics, the team mapped this defect and uncovered a brand-new, H3N2-specific role for Rab11B during viral entry.
CLICK HERE FOR MORE HEALTH STORIES
This discovery challenged the scientific assumption that all flu viruses enter cells the same way.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
“Viruses are like pirates from different countries hijacking someone’s ship,” Bruce said. “Different viruses, like different types of pirates, use different methods to get onboard.”
This discovery challenged the scientific assumption that all flu viruses enter cells the same way. (iStock)
“We had previously thought that all flu viruses used the same way to get into a cell, but we discovered that this is not true,” she went on. “H1N1 and H3N2 need different proteins to get in, and if you get rid of the right protein, a specific virus can’t get in.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
While these findings identify a critical cellular pathway for viral entry, the study was conducted using isolated cells, the researchers acknowledged.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Further research is needed to determine whether blocking the protein is safe and effective within a live, complex human respiratory system.
Bruce and the team hope to conduct further research to determine whether this Rab11B-dependency is a fundamental property of H3N2, or if it’s a trait unique to currently circulating flu strains.
NEWYou can now listen to Fox News articles!
Eating processed meat like ham, sausage and bacon may be linked to a higher risk of certain types of cancer, according to new research.
While health organizations have already confirmed that processed meat can contribute to colon cancer, this study looked closer at cancers in the upper digestive tract, where the link has historically been less clear.
To understand these connections, researchers from the European Prospective Investigation into Cancer and Nutrition (EPIC), one of the world’s largest long-term nutrition and cancer cohorts, tracked the health and diets of 450,112 people across Europe for an average of 14 years.
FREQUENT HEARTBURN MAY BE A WARNING SIGN OF A MORE DANGEROUS CONDITION, DOCTOR SAYS
The study group included 131,426 men and 318,686 women, according to the study’s press release.
During the follow-up period, 876 people developed stomach cancer and 215 people developed esophageal adenocarcinoma, which is cancer of the tube connecting the mouth to the stomach.
For female participants, eating both processed meat and white meat was linked to an increased risk of developing the disease. (iStock)
Researchers tracked where the stomach cancers grew, separating them into the upper part of the stomach near the throat and the lower part of the stomach.
The researchers also sorted the tumors into two categories based on how the cancer cells appeared under a microscope: intestinal, which forms more organized structures, and diffuse, in which the cells are more scattered throughout the tissue.
BACTERIA IN YOUR MOUTH MAY TRAVEL TO THE GUT AND TRIGGER STOMACH CANCER, RESEARCH FINDS
After adjusting for other lifestyle factors, the researchers found that for every extra 30 grams of processed meat a person ate per day, their overall risk of stomach cancer went up by 9%. Eating that same extra 30 grams a day was also linked to a 13% higher risk of esophageal adenocarcinoma.
A standard single slice of regular deli-sliced ham or lunch meat averages around 28 grams, according to USDA data and nutritional tracking databases.
An extra 20 grams of white meat, such as chicken and turkey, was linked to a 12% higher risk of cancer in the main body of the stomach. (iStock)
An extra 20 grams of white meat, such as chicken or turkey, was linked to a 12% higher risk of cancer in the main body of the stomach, the researchers noted.
The study also revealed differences between men and women. For male participants, only processed meat showed a clear, statistically significant link to a higher risk of stomach cancer. For female participants, however, eating both processed meat and white meat was linked to an increased risk.
CLICK HERE FOR MORE HEALTH STORIES
These findings align with global health benchmarks, particularly those established by the World Health Organization’s International Agency for Research on Cancer.
The agency has long classified processed meat as a known human carcinogen, primarily due to its strong, well-documented links to colorectal cancer.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
However, health organizations have also consistently pointed to a potential, yet less definitive, relationship between these meats and cancers of the stomach.
Eating 30 grams of processed meat a day, or the equivalent to one slice of ham, was linked to a 13% higher risk of esophageal adenocarcinoma. (iStock)
Further scientific investigation is needed to confirm the findings and to account for other underlying risk factors, such as certain stomach infections, which could interact with dietary habits.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
A key limitation of the study is its reliance on self-reported diets, which can sometimes lead to inaccuracies in how participants recall their meat consumption over time, the researchers noted.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
The findings were published in the International Journal of Cancer.
Fox News Digital reached out to the researchers requesting comment.
-
Lifestyle31 minutes agoHow having zero points in tennis — or ‘love’ — came to sound so sweet
-
Technology43 minutes agoAmazon develops a warehouse robot workers can speak to
-
World45 minutes agoAlbino buffalo nicknamed ‘Donald Trump’ becomes sensation at Bangladesh’s national zoo for its blond hair
-
Politics51 minutes agoThe growing list of controversies threatening Democrat Graham Platner’s Maine Senate bid
-
Health58 minutes agoNew cancer vaccine delivers stunning result against one of the deadliest skin cancers
-
Sports1 hour agoFan disrupts NBA Finals Game 1 while trying to take selfie with Spurs’ Victor Wembanyama
-
Business1 hour agoHow Google’s 32-million mosquito project could change California’s battle against dengue
-
Entertainment1 hour agoAfter ‘Barbie’ success, Mattel looks to He-Man for another box-office lift
